ArticleInternational journal of legal medicine2025
Elevated serum and cerebrospinal fluid levels of the synaptophysin and neurogranin with its altered brain expression in the early phase of traumatic brain injury as a potential marker of synaptic injury.
Article in International journal of legal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Utility of selected neuroinflammatory markers following lethal traumatic brain injury: a combined biofluid and tissue-based assessment of TNF-α, CX3CL1, TNFR1, TNFR2 and CX3CR1 expression.International journal of legal medicine · 2026Article
- Profiling of hypoxic and extracellular matrix remodeling markers in biofluids and cerebral tissue after traumatic brain injury: expression and signaling crosstalk of HIF-1α, MMP-9/14 and EPHA2.International journal of legal medicine · 2026Article
- Evaluation of Sirtuin 1 (SIRT1) and Sirtuin 3 (SIRT3) in serum and cerebrospinal fluid following fatal traumatic brain injury.International journal of legal medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic brain injury (TBI) is a significant contributor to mortality and is frequently linked to forensic and criminological inquiries. In the context of scientific and clinical progress, there is a continual need to explore new bioassays and data analysis methods for use in TBI diagnostics in both ante- and post-mortem individuals. Predominantly intra- and extra-synaptic proteins, such as synaptophysin (SYP) and neurogranin (NRGN) were to date potentially investigated as markers for TBI regarding their usefulness as a set of reliable biomarkers. This study aimed to elucidate and identify if elevated SYP and NRGN concentration levels in biofluids such as serum and CSF are seen in cases of TBI in a population-based autopsy screening. An additional comparative examination of the SYP and NRGN protein expression in the obtained brain tissue by performing immunohistochemical staining was done. The study was carried out using cases (n = 20) of severe head injury suspected as the cause of death and control cases (n = 20) of sudden death in the mechanism of cardiopulmonary failure. The biofluids, such as serum and cerebrospinal fluid (CSF) were collected within ∼24 h after death and compared using ELISA test. Brain specimens were similarly collected during forensic autopsies. In our study, we observed the elevated concentration levels of SYP and NRGN in serum and CSF. In anti-SYP staining of the frontal cortex, a significant, generalized reduction in the reaction was observed, within neurons and neuropil in the head injury group. In anti-NRGN staining of the frontal cortex, a significant, generalized homogenization of the reaction was observed both within the neuronal bodies and their axons. The possible implementation of synaptic biomarker assays offers an interesting and novel tool for investigation and research regarding TBI diagnosis and pathogenesis. This surrogate synatpic assay could be useful in clinical prognosis and risk calculation of non-fatal cases of TBI, regarding the development of neurodegenerative conditions of TBI individuals.
Indexed as
Identifiers
40146393What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.